Brandon M Imp1,2, Leah H Rubin3, Phyllis C Tien4,5, Michael W Plankey6, Elizabeth T Golub7, Audrey L French8,9, Victor G Valcour1. 1. Memory and Aging Center, Department of Neurology. 2. Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey. 3. Department of Psychiatry, University of Illinois at Chicago. 4. Department of Medicine, University of California-San Francisco. 5. Division of Infectious Diseases, Veterans Affairs Medical Center, San Francisco, California. 6. Division of Infectious Diseases, Department of Medicine, Georgetown University Medical Center, Washington, D. C. 7. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 8. CORE Center, Cook County Health and Hospitals System. 9. Department of Medicine, Division of Infectious Diseases, Rush University Medical Center, Chicago, Illinois.
Abstract
BACKGROUND: Cognitive impairment persists despite suppression of plasma human immunodeficiency virus (HIV) RNA. Monocyte-related immune activation is a likely mechanism. We examined immune activation and cognition in a cohort of HIV-infected and uninfected women from the Women's Interagency HIV Study (WIHS). METHODS: Blood levels of activation markers, soluble CD163 (sCD163), soluble CD14 (sCD14), CRP, IL-6, and a gut microbial translocation marker (intestinal fatty acid binding protein (I-FABP)) were measured in 253 women (73% HIV-infected). Markers were compared to concurrent (within ± one semiannual visit) neuropsychological testing performance. RESULTS: Higher sCD163 levels were associated with worse overall performance and worse verbal learning, verbal memory, executive function, psychomotor speed, and fine motor skills (P < .05 for all comparisons). Higher sCD14 levels were associated with worse verbal learning, verbal memory, executive function, and psychomotor speed (P < .05 for all comparisons). Among women with virological suppression, sCD163 remained associated with overall performance, verbal memory, psychomotor speed, and fine motor skills, and sCD164 remained associated with executive function (P < .05 for all comparisons). CRP, IL-6, and I-FABP were not associated with worse cognitive performance. CONCLUSIONS: Monocyte activation was associated with worse cognitive performance, and associations persisted despite viral suppression. Persistent inflammatory mechanisms related to monocytes correlate to clinically pertinent brain outcomes.
BACKGROUND:Cognitive impairment persists despite suppression of plasma human immunodeficiency virus (HIV) RNA. Monocyte-related immune activation is a likely mechanism. We examined immune activation and cognition in a cohort of HIV-infected and uninfected women from the Women's Interagency HIV Study (WIHS). METHODS: Blood levels of activation markers, soluble CD163 (sCD163), soluble CD14 (sCD14), CRP, IL-6, and a gut microbial translocation marker (intestinal fatty acid binding protein (I-FABP)) were measured in 253 women (73% HIV-infected). Markers were compared to concurrent (within ± one semiannual visit) neuropsychological testing performance. RESULTS: Higher sCD163 levels were associated with worse overall performance and worse verbal learning, verbal memory, executive function, psychomotor speed, and fine motor skills (P < .05 for all comparisons). Higher sCD14 levels were associated with worse verbal learning, verbal memory, executive function, and psychomotor speed (P < .05 for all comparisons). Among women with virological suppression, sCD163 remained associated with overall performance, verbal memory, psychomotor speed, and fine motor skills, and sCD164 remained associated with executive function (P < .05 for all comparisons). CRP, IL-6, and I-FABP were not associated with worse cognitive performance. CONCLUSIONS: Monocyte activation was associated with worse cognitive performance, and associations persisted despite viral suppression. Persistent inflammatory mechanisms related to monocytes correlate to clinically pertinent brain outcomes.
Authors: Kalpana J Kallianpur; Victor G Valcour; Sukalaya Lerdlum; Edgar Busovaca; Melissa Agsalda; Pasiri Sithinamsuwan; Thep Chalermchai; James L K Fletcher; Somporn Tipsuk; Cecilia M Shikuma; Bruce T Shiramizu; Jintanat Ananworanich Journal: AIDS Date: 2014-07-17 Impact factor: 4.177
Authors: Tricia H Burdo; Margaret R Lentz; Patrick Autissier; Anitha Krishnan; Elkan Halpern; Scott Letendre; Eric S Rosenberg; Ronald J Ellis; Kenneth C Williams Journal: J Infect Dis Date: 2011-07-01 Impact factor: 5.226
Authors: Leah H Rubin; Maria Pyra; Judith A Cook; Kathleen M Weber; Mardge H Cohen; Eileen Martin; Victor Valcour; Joel Milam; Kathryn Anastos; Mary A Young; Christine Alden; Deborah R Gustafson; Pauline M Maki Journal: J Neurovirol Date: 2015-09-24 Impact factor: 2.643
Authors: Victor G Valcour; Leah H Rubin; Mary U Obasi; Pauline M Maki; Marion G Peters; Susanna Levin; Howard A Crystal; Mary A Young; Wendy J Mack; Mardge H Cohen; Christopher B Pierce; Adaora A Adimora; Phyllis C Tien Journal: J Acquir Immune Defic Syndr Date: 2016-07-01 Impact factor: 3.731
Authors: Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly Journal: Nat Med Date: 2009-06-21 Impact factor: 53.440
Authors: Maria L Alcaide; Anita Parmigiani; Suresh Pallikkuth; Margaret Roach; Riccardo Freguja; Marina Della Negra; Hector Bolivar; Margaret A Fischl; Savita Pahwa Journal: PLoS One Date: 2013-05-28 Impact factor: 3.240
Authors: Petronela Ancuta; Anupa Kamat; Kevin J Kunstman; Eun-Young Kim; Patrick Autissier; Alysse Wurcel; Tauheed Zaman; David Stone; Megan Mefford; Susan Morgello; Elyse J Singer; Steven M Wolinsky; Dana Gabuzda Journal: PLoS One Date: 2008-06-25 Impact factor: 3.240
Authors: Archana Asundi; Yvonne Robles; Tyler Starr; Alan Landay; Jennifer Kinslow; Joshua Ladner; Laura White; Rebeca M Plank; Kathleen Melbourne; Daniel Weisholtz; Monica Bennett; Hong Pan; Emily Stern; Alexander Lin; Daniel R Kuritzkes; Nina H Lin Journal: J Acquir Immune Defic Syndr Date: 2019-08-15 Impact factor: 3.731
Authors: L Arnoldo Muñoz-Nevárez; Brandon M Imp; Michael A Eller; Francis Kiweewa; Jonah Maswai; Christina Polyak; Omalla Allan Olwenyi; I Elaine Allen; Eric Rono; Benedetta Milanini; Hannah Kibuuka; Julie A Ake; Leigh Anne Eller; Victor G Valcour Journal: J Neurovirol Date: 2019-08-29 Impact factor: 2.643
Authors: Sarah F Benki-Nugent; Ira Martopullo; Tony Laboso; Nancy Tamasha; Dalton C Wamalwa; Kenneth Tapia; Agnes Langat; Elizabeth Maleche-Obimbo; Christina M Marra; Paul Bangirana; Michael J Boivin; Grace C John-Stewart Journal: J Acquir Immune Defic Syndr Date: 2019-05-01 Impact factor: 3.731
Authors: P Lorenzo Bozzelli; Tao Yin; Valeria Avdoshina; Italo Mocchetti; Katherine E Conant; Kathleen A Maguire-Zeiss Journal: Glia Date: 2019-05-23 Impact factor: 7.452